In July 2017, MAPS raised $56,485 in new donations and pledges from 365 supporters. In the same month, we launched our summer fundraising campaign to raise $60,000 for the Zendo Project, a psychedelic harm reduction and peer counseling program. Donate and learn more at zendoproject.org.
MAPS is moving forward with our research into MDMA-assisted psychotherapy for the treatment of PTSD. Phase 3 studies will cost between $25-$35 million for both FDA and European Medicines Agency (EMA) approval. With $12.5 million in hand, there’s still a funding gap we need to close.
We extend a special thanks to those who so generously supported MAPS last month:
- Patricia & Richard Simon ($10,000)
- Sally & Ted Schwartz ($2,500)
- Kevin Herbert ($2,000)
- Fernanda Weiden ($1,535)
- Grant Leonard ($1,100)
- John & Barbara Crary ($1,000)
- Robert & Nancy Ley ($1,000)
- Robert Gansser ($1,000)
- Sahajia Sarkisian ($1,000)
- William F. Harrison ($1,000)
MDMA/PTSD Phase 3 GMP Drug
- Michael Mullins ($1,000)
MDMA/PTSD Israel Study
- Michael & Anita Siegal Family Foundation ($4,000)
- Erik Bouchard ($1,000)
- Peter Taubkin ($1,000)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate